U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H15N.ClH
Molecular Weight 209.715
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BICIFADINE HYDROCHLORIDE

SMILES

Cl.[H][C@]12C[C@]1(CNC2)C3=CC=C(C)C=C3

InChI

InChIKey=OTZOPAFTLUOBOM-LYCTWNKOSA-N
InChI=1S/C12H15N.ClH/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12;/h2-5,11,13H,6-8H2,1H3;1H/t11-,12+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C12H15N
Molecular Weight 173.2542
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bicifadine (DOV-220075) is not a narcotic and is well-tolerated and, in preclinical studies, has been shown not to act at any opiate receptor, but inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine:serotonin:dopamine of 1:2:17. Bicifadine was in Phase II clinical trial for pain caused by diabetic neuropathy, in addition, was in phase III clinical trial to treat Chronic Low Back Pain, but that studies were discontinued

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
5.0 µM [Ki]
Target ID: P31645
Gene ID: 6532.0
Gene Symbol: SLC6A4
Target Organism: Homo sapiens (Human)
2.4 µM [Ki]
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
5.2 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1780 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICIFADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
34271 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICIFADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.63 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICIFADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.2%
BICIFADINE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
200 mg single, oral (unknown)
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, ADULT
n = 8
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Population Size: 8
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
2007 Dec
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.
2007 Jun
Patents

Patents

Sample Use Guides

400 mg bid or tid for one year
Route of Administration: Oral
Bicifadine interactions with neurotransmitter transporters, receptors, and ion channels were tested, using the radioligand-receptor binding screen. Bicifadine inhibited [125I]RTI-55 binding to sites on recombinant human 5-HT, NE, and DA transporters with moderate (micromolar) but equivalent affinities (1:2:2, respectively). Subsequent functional tests indicated that bicifadine potently inhibited the uptake of [3H]NE and [3H]5-HT by cell lines expressing recombinant human monoamine transporters (IC50 = 55 and 117 nM, respectively), whereas its potency in blocking [3H]DA uptake was approximately one order of magnitude lower (IC50 = 910 nM) (1:2:17, respectively).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:06:47 UTC 2023
Edited
by admin
on Fri Dec 15 16:06:47 UTC 2023
Record UNII
OE6G20P68T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BICIFADINE HYDROCHLORIDE
MART.   USAN  
USAN  
Official Name English
BICIFADINE HYDROCHLORIDE [MART.]
Common Name English
CL-220075
Code English
BICIFADINE HCL
Common Name English
(±)-1-P-TOLYL-3-AZABICYCLO(3.1.0)HEXANE HYDROCHLORIDE
Common Name English
BICIFADINE HYDROCHLORIDE [USAN]
Common Name English
CL 220,075
Code English
3-AZABICYCLO(3.1.0)HEXANE, 1-(4-METHYLPHENYL)-, HYDROCHLORIDE, (±)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C81047
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID20985128
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
CAS
66504-75-4
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
PUBCHEM
46783598
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
ChEMBL
CHEMBL511099
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
DRUG BANK
DBSALT000817
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
FDA UNII
OE6G20P68T
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
EVMPD
SUB32896
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
SMS_ID
100000126278
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
MESH
C034438
Created by admin on Fri Dec 15 16:06:48 UTC 2023 , Edited by admin on Fri Dec 15 16:06:48 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY